Daewoong Pharmaceutical announce Publication of Phase 3 Study of 'Envlo', a new treatment for Diabetes, in the International SCIE Journal

Apr 24, 2023

Seoul [South Korea], April 24 (ANI/PRNewswire): The research results of Daewoong Pharmaceutical's SGLT-2 inhibitor new drug, 'Envlo', have been internationally acknowledged.

Daewoong Pharmaceutical has obtained approval for SGLT2i + metformin combination drug Envlomet

Jul 19, 2023

Seoul [South Korea], July 19: Daewoong Pharmaceutical obtained approval for a SGLT-2 inhibitor+metformin combination drug in just one month after the release of Envlo...